Table 1. Demographic data and clinical characteristics for each cohort.

Variable		Oropharynx (n=45) %	Oral (n=61) %	p-value (chi Sqr)	Normal (n=81) %
Age	≤60	24 (53.3%)	24 (39.3%)	0.153	64 (79.0%)
	>60	21 (46.7%)	37 (60.7%)		16 (19.8%)
Gender	Male	38 (84.4%)	30 (49.2%)	<0.001	15 (18.5%)
	Female	7 (15.6%)	31 (50.8%)		66 (81.5%)
Smoking	Never	14 (31.1%)	26 (42.6%)	0.227	35 (43.2%)
	Ever	31 (68.9%)	35 (57.4%)		39 (48.1%)
Alcohol	Never	7 (15.6%)	15 (24.6%)	0.257	11 (13.6%)
	Ever	38 (84.4%)	46 (75.4%)		62 (76.5%)
Clinical T Stage	T1	5 (11.1%)	27 (45.8%)	NA
	T2	30 (66.7%)	19 (32.2%)
	T3	5 (11.1%)	4 (6.8%)
	T4	5 (11.1%)	9 (15.3%)
Clinical N Stage	N0	1 (2.2%)	48 (78.7%)	<0.001
	N+	44 (97.8%)	13 (21.3%)
Clinical M Stage	M0	44 (97.8%)	61 (100%)	0.425*
	M1	1 (2.2%)	0
Overall Clinical Stage	I	0	25 (42.4%)	<0.001
	II	1 (2.2%)	14 (23.7%)
	III	5 (11.1%)	8 (13.6%)
	IV	39 (86.7%)	12 (20.3%)
Pathologic T Stage (n=47)	T1	4 (36.4%)	33 (56.9%)	NA
	T2	7 (63.6%)	15 (25.9%)
	T3	0	2 (3.4%)
	T4	0	8 (13.8%)
Pathologic N Stage (n=48)	N0/NX	1 (9.1%)	42 (70.0%)	<0.001
	N+	10 (90.9%)	18 (30.0%)
Overall Pathologic Stage	I	0	28 (48.3%)	NA
	II	1 (9.1%)	9 (15.5%)
	III	2 (18.2%)	4 (6.9%)
	IV	8 (72.7%)	17 (29.3%)
p16 Tissue	negative	4 (8.9%)	59 (96.7%)	<0.001
	positive	41 (91.1%)	2 (3.3%)
HPV Oral rinse	HPV 16 positive	33 (73.3%) *	6 (9.8%)	NA	2 (2.5%)
	HPV 18 positive	1 (2.2%)	0		0 (0.0%)
	HR-other HPV positive alone	2 (4.4%)	2 (3.3%)		1 (1.2%)
	negative	9 (20.0%)	53 (86.9%)		78 (96.3%)

Comparison of the oropharynx and oral cavity cohorts was carried out by the Chi-square test of association.

^*18 of 33 were also positive for another HPV serotype.